Bicara Therapeutics INC Form 4 insider transactions

Jennifer Larson, Chief Financial Officer of Bicara Therapeutics Inc., received 285,000 shares of common stock on August 12, 2026.

Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc., sold 12,500 shares of common stock on August 10, 2026 for $27.97 per share.

Claire Mazumdar, Chief Executive Officer and a Director of Bicara Therapeutics Inc., sold 10,000 shares of common stock on August 10, 2026 for $27.98 per share.

Ryan Cohlhepp, President and COO and a Director of Bicara Therapeutics Inc., sold 18,750 shares of common stock on August 10, 2026 for $27.98 per share.

Jeremy Bender, a Director of Bicara Therapeutics Inc., received 38,950 shares of common stock on July 28, 2026.

Christy J. Oliger, a Director of Bicara Therapeutics Inc., received 38,950 shares of common stock on July 28, 2026.

Claire Mazumdar, Chief Executive Officer and a Director of Bicara Therapeutics Inc., sold 10,000 shares of common stock on July 10, 2026.

Bicara Therapeutics Inc. reports that Ryan Cohlhepp, President and COO, sold a significant number of common shares and exercised stock options as part of a pre-arranged trading plan.

Bicara Therapeutics Inc. Chief Financial Officer, Ivan Hyep, reported transactions involving the sale of company stock and the acquisition of stock options on July 8, 2026.

RA Capital Management, L.P. and its affiliates report the grant of a stock option to Jake Simson, a director and partner at RA Capital Management, for 19,475 shares of common stock.

Christopher Bowden, a Director at Bicara Therapeutics Inc., acquired stock options for 19,475 shares.

Kate Haviland, a Director at Bicara Therapeutics Inc., acquired stock options for 19,475 shares with an exercise price of $20.56.

Kiran Mazumdar-Shaw, a Director at Bicara Therapeutics Inc., acquired stock options for 19,475 shares.

Director Scott M. Robertson was granted 19,475 stock options in Bicara Therapeutics Inc. as part of standard equity compensation.

Director Michael Powell was granted 19,475 stock options in Bicara Therapeutics Inc. as part of standard equity compensation.

Director Jake Simson was granted 19,475 stock options in Bicara Therapeutics Inc. as part of his service arrangement.

Bicara Therapeutics CFO Ivan Hyep executed a Rule 10b5-1 trading plan, acquiring shares at a lower price and selling others at a higher average price.

Claire Mazumdar, CEO of Bicara Therapeutics, reported transactions involving the purchase and sale of company stock, executed under a Rule 10b5-1 trading plan.

Bicara Therapeutics reports on insider stock transactions, including option exercises and share sales under a 10b5-1 plan.

Bicara Therapeutics reports the grant of stock options to Chief Medical Officer William Schelman, with vesting over four years.

Chief Medical Officer David Raben exercised options and sold 5,500 shares of Bicara Therapeutics common stock under a 10b5-1 plan.

Bicara Therapeutics CFO Ivan Hyep exercised options and sold 9,200 shares of common stock under a Rule 10b5-1 trading plan.

CEO Claire Mazumdar exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

President and COO Ryan Cohlhepp exercised options and sold 12,500 shares of Bicara Therapeutics common stock.

Bicara Therapeutics' Chief Medical Officer, David Raben, exercised options and sold 5,500 shares of common stock under a pre-arranged trading plan.

Bicara Therapeutics Chief Financial Officer Ivan Hyep executed a pre-planned sale of 9,200 common shares following the exercise of stock options.

Bicara Therapeutics CEO Claire Mazumdar executed a series of option exercises and subsequent share sales totaling 14,900 shares under a Rule 10b5-1 plan.

Bicara Therapeutics President and COO Ryan Cohlhepp executed pre-planned sales of 12,500 common shares following the exercise of stock options.

Bicara Therapeutics CEO Claire Mazumdar executed planned sales of common stock following the exercise of stock options in early March 2026.

Bicara Therapeutics' President and COO, Ryan Cohlhepp, executed a pre-planned transaction involving the exercise of stock options and subsequent sale of common stock.